Zymeworks Inc. (NYSE:ZYME) to Post Q1 2025 Earnings of ($0.43) Per Share, HC Wainwright Forecasts

Zymeworks Inc. (NYSE:ZYME) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Zymeworks in a research note issued on Tuesday, June 18th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of ($0.43) for the quarter. HC Wainwright has a “Neutral” rating and a $10.00 price target on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS and Q4 2025 earnings at ($0.48) EPS.

Zymeworks (NYSE:ZYME) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.11). The business had revenue of $10.03 million during the quarter, compared to analyst estimates of $17.98 million. Zymeworks had a negative net margin of 249.63% and a negative return on equity of 28.37%.

A number of other analysts also recently issued reports on the stock. Wells Fargo & Company cut their price target on shares of Zymeworks from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. Citigroup decreased their price target on shares of Zymeworks from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, May 3rd.

Zymeworks Price Performance

Shares of NYSE ZYME opened at $8.52 on Wednesday. The company has a 50 day simple moving average of $8.86 and a 200-day simple moving average of $10.01. The company has a market capitalization of $602.45 million, a P/E ratio of -4.76 and a beta of 1.18. Zymeworks has a 1 year low of $6.01 and a 1 year high of $13.14.

Institutional Investors Weigh In On Zymeworks

Institutional investors have recently modified their holdings of the company. Gladius Capital Management LP lifted its position in shares of Zymeworks by 36.5% during the 3rd quarter. Gladius Capital Management LP now owns 3,940 shares of the company’s stock worth $25,000 after purchasing an additional 1,053 shares during the last quarter. AlphaMark Advisors LLC acquired a new position in Zymeworks in the first quarter valued at $32,000. New York State Teachers Retirement System acquired a new position in Zymeworks in the fourth quarter valued at $50,000. AJOVista LLC acquired a new position in Zymeworks in the fourth quarter valued at $66,000. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of Zymeworks during the third quarter worth about $80,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.